Astera Labs reports its Q1 results today with an extraordinary backdrop: the stock has nearly doubled in a month while its own CEO has been selling into every uptick.
The insider activity is hard to ignore. Founder and CEO Jitendra Mohan sold shares across multiple tranches on April 17 and April 20, raising over $16 million in total at prices around $168–$176. An independent director, Stefan Dyckerhoff, sold another roughly $2.3 million over the same two days. The stock has since rallied another 23% above those sale prices to close at $215.69 on Tuesday. That divergence — insiders cashing out aggressively while the stock keeps climbing — is the central tension heading into tonight's print.
Short sellers, by contrast, have been retreating. Short interest in the float has dropped from a peak near 9.7% in mid-April to 7.5% now, a 12% reduction over the past month. Borrow costs are negligible at under 0.5%, and availability is loose — more than enough supply remains in the lending pool for new shorts to establish positions if they choose to. The ORTEX short score has also fallen steadily, from above 51 on April 22 to 46 today, reinforcing that short-side pressure is easing rather than building. The borrow market sends no squeeze signal whatsoever.
Options traders have turned noticeably more defensive into the print. The put/call ratio jumped to 0.88 on Tuesday — nearly three standard deviations above its 20-day mean of 0.82 and the most elevated defensive positioning seen in months. That sits well below the 52-week high of 1.03, so it is not extreme in absolute terms, but the sharp single-day move is a clear sign that hedging activity intensified as the earnings date arrived.
The analyst debate reflects the valuation challenge baked into an 84% one-month move. Citigroup maintained its Buy rating in early April but trimmed its target to $200 — now below the current price. Two new Neutral initiations arrived within the past two weeks: UBS at $180 and Rothschild at $153, both well below where the stock is trading. RBC and Loop Capital carry constructive Outperform and Buy ratings at $225 and $250 respectively, suggesting the bull case rests on AI and data centre connectivity spend sustaining premium growth. Bears — and the two new Neutral starters — point to a P/E now running above 70x and EV/EBITDA near 57x as multiples that leave little room for any guidance miss. EPS surprise has ranked only in the 20th percentile historically, adding an extra layer of caution.
The print will test whether ALAB's Q1 numbers and forward guidance can justify a valuation that has re-rated sharply higher even as the company's own founders chose to monetise — and whether the stock can hold its gains with two fresh Neutral ratings already anchored well below the current price.
See the live data behind this article on ORTEX.
Open ALAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
